Maša Alečković, Zheqi Li, Ningxuan Zhou, Xintao Qiu, Bethlehem Lulseged, Pierre Foidart, Xiao-Yun Huang, Kodie Garza, Shaokun Shu, Nikolas Kesten, Rong Li, Klothilda Lim, Ana C Garrido-Castro, Jennifer L Guerriero, Jun Qi, Henry W Long, Kornelia Polyak
Immune checkpoint inhibition combined with chemotherapy is currently approved as first-line treatment for patients with advanced PD-L1-positive triple-negative breast cancer (TNBC). However, a significant proportion of metastatic TNBC is PD-L1-negative and, in this population, chemotherapy alone largely remains the standard-of-care and novel therapeutic strategies are needed to improve clinical outcomes. Here, we describe a triple combination of anti-PDL-1 immune checkpoint blockade, epigenetic modulation thorough BET bromodomain inhibition (BBDI), and chemotherapy with paclitaxel that effectively inhibits both primary and metastatic tumor growth in two different syngeneic murine models of TNBC...
September 7, 2023: Molecular Cancer Therapeutics